Filing Details

Accession Number:
0001140361-13-015214
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-04-02 16:46:35
Reporting Period:
2013-04-01
Filing Date:
2013-04-02
Accepted Time:
2013-04-02 16:46:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1104506 Insmed Inc INSM Pharmaceutical Preparations (2834) 541972729
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1402051 William Lewis C/O Insmed Inc.
9 Deer Park Drive, Suite C
Monmouth Junction NJ 08852
President And Ceo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-04-01 9,816 $7.58 34,154 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option-Right to Buy $3.40 2013-09-10 2022-09-10 708,314 708,314 Direct
Common Stock Stock Option-Right to Buy $4.55 2013-09-28 2022-09-28 186,170 186,170 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2022-09-10 708,314 708,314 Direct
2022-09-28 186,170 186,170 Direct
Footnotes
  1. Open market purchase pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.46 to $7.73, inclusive. The reporting person undertakes to provide to Insmed Incorporated, any security holder of Insmed Incorporated or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  3. These options shall become exercisable with respect to 25% of the shares of common stock subject to this grant on September 10, 2013, the first anniversary of the date of grant, and with respect to an additional 12.5% of the shares of common stock subject to this grant on each sixth month anniversary of September 10, 2013 thereafter through September 10, 2016.
  4. These options shall become exercisable with respect to 25% of the shares of common stock subject to this grant on September 28, 2013, the first anniversary of the date of grant, and with respect to an additional 12.5% of the shares of common stock subject to this grant on each sixth month anniversary of September 28, 2013 thereafter through September 28, 2016.